Physician profile
Stephen C Young
NPI 1609849637
$7,182.45
in general payments reported to CMS, 2019-2025
52 companies · $1,323 in 2025
The $1,323 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,055 · 2020: $610 · 2021: $365 · 2022: $775 · 2023: $861 · 2024: $1,194 · 2025: $1,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,378.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,651.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $636.52 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $509.97 | 2019-2025 | Evenity, Prolia, Tepezza |
| Sanofi-Aventis U.S. LLC | $470.58 | 2019-2024 | |
| Abbott Laboratories | $431.39 | 2019-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $360.70 | 2019-2024 | Lokelma, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.50 | 2019-2025 | Jardiance |
| Insulet Corporation | $266.81 | 2019-2025 | Omnipod |
| Abbvie INC. | $244.67 | 2019-2024 | Synthroid, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $231.11 | 2022-2025 | |
| Dexcom, INC. | $192.10 | 2019-2025 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $171.08 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Amneal Pharmaceuticals LLC | $136.19 | 2019-2025 | Unithroid |
| Ibsa Pharma INC. | $115.41 | 2019-2023 | Tirosint, Licart |
| Pfizer INC. | $99.05 | 2019-2025 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.